FDA OKs Genentech’s Tecentriq as Adjuvant Treatment
This article is for subscribers only.
The U.S. Food and Drug Administration said it approved Genentech’s Tecentriq or atezolizumab, for adjuvant treatment for patients with non-small cell lung cancer, according to the agency’s website.
To view the source of this information click here